View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 3, 2016

VM BioPharma receives South Korea MFDS approval for Phase II trial of VM202 to treat IHD

South Korean-based ViroMed’s US biopharmaceutical division VM BioPharma has secured Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety in Korea (MFDS) to conduct the Phase II clinical trial of VM202 for ischemic heart disease (IHD).

South Korean-based ViroMed’s US biopharmaceutical division VM BioPharma has secured Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety in Korea (MFDS) to conduct the Phase II clinical trial of VM202 for ischemic heart disease (IHD).

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

VM202 is VM BioPharma’s patented gene therapy drug, which generates two isoforms of hepatocyte growth factor (HGF) protein after being injected into the cardiac muscles of the patient.

The protein triggers angiogenesis and acts as a neurotrophic factor resulting to the formation of new microvasculature thereby inducing regeneration of nerve cells.

The trial has been designed to assess the safety and tolerability of VM202, while its secondary efficacy endpoint is to determine the cardiac function and output.

"Data from the Phase I trial of VM202 in IHD suggests that VM202 may be a promising option for IHD treaters and patients."

It will involve 108 patients with IHD who previously received a percutaneous coronary intervention (PCI) for acute myocardial infarction before 30 days of enrolment within the study.

The patients will be injected with VM202 percutaneously through the endocardial route using an innovative therapeutic catheter.

ViroMed chief scientific officer Dr Sunyoung Kim said: "Data from the Phase I trial of VM202 in IHD suggests that VM202 may be a promising option for IHD treaters and patients, where there is currently an unmet need for those that have developed necrosis and / or fibrosis of the myocardium despite reperfusion therapy such as percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)."

Two Phase III studies are currently evaluating the safety and efficacy of VM202 by individually treating adult patients with painful diabetic peripheral neuropathy (DPN) and ischemic diabetic foot ulcer.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena